

Pharmaceutical Management Agency

Section H Update for Hospital Pharmaceuticals

Effective 1 August 2018



Contents

Summary of decisions effective 1 August 2018.....	3
Section H changes to Part II	8
Index.....	16

Summary of decisions

EFFECTIVE 1 AUGUST 2018

- Aluminium hydroxide with magnesium hydroxide and simeticone (e.g. Mylanta) tab 200 mg with magnesium hydroxide 200 mg and simeticone 20 mg – amended chemical name and presentation description)
- Aluminium hydroxide with magnesium hydroxide and simeticone (e.g. Mylanta Double Strength) oral liq 400 mg with magnesium hydroxide 400 mg and simeticone 30 mg per 5 ml – amended chemical name and presentation description)
- Aqueous cream (Pharmacy Health SLS-free) crm 100 g – price increase and addition of HSS
- Atropine sulphate (Martindale) inj 600 mcg per ml, 1 ml ampoule – new listing and addition of HSS
- Atropine sulphate (AstraZeneca) inj 600 mcg per ml, 1 ml ampoule – to be delisted 1 October 2018
- Baclofen (Pacifen) tab 10 mg – price increase and addition of HSS
- Beractant (Survanta) soln 200 mg per 8 ml vial – to be delisted 1 January 2019
- Betamethasone valerate crm 0.1%, 50 g (Beta Cream) and oint 0.1%, 50 g (Beta Ointment) – price increase and addition of HSS
- Betamethasone valerate (Beta Scalp) scalp app 0.1%, 100 ml – addition of HSS
- Bosentan (Bosentan Dr Reddy's) tab 62.5 mg and 125 mg – new listing and addition of HSS
- Bosentan (Bosentan-Mylan) tab 62.5 mg and 125 mg – to be delisted 1 December 2018
- Budesonide (SteroClear) nasal spray 50 mcg per dose and 100 mcg per dose – new listing and addition of HSS
- Budesonide (Butacort Aqueous) nasal spray 50 mcg per dose and 100 mcg per dose – to be delisted 1 October 2018
- Cefalexin (Cefalexin Sandoz) grans for oral liq 25 mg per ml and 50 mg per ml – price increase and addition of HSS
- Ciprofloxacin (Cipflox) inj 2 mg per ml, 100 ml bag – price increase and addition of HSS
- Clomipramine hydrochloride (Apo-Clomipramine) tab 10 mg and 20 mg – price increase and addition of HSS
- Clonidine hydrochloride (Clonidine BNM) tab 25 mcg – price increase and addition of HSS
- Clonidine hydrochloride (Medsurge) inj 150 mcg per ml, 1 ml ampoule – new listing and addition of HSS

Summary of decisions – effective 1 August 2018 (continued)

- Clonidine hydrochloride (Catapres) inj 150 mcg per ml, 1 ml ampoule – to be delisted 1 October 2018
 - Cyclophosphamide (Endoxan) inj 1 g and 2 g vials – price increase and addition of HSS
 - Dexamethasone (Dexamethasone) tab 0.5 mg and 4 mg – price increase and addition of HSS
 - Dexamfetamine sulfate (PSM) tab 5 mg – price increase and addition of HSS
 - Diclofenac sodium tab EC 50 mg (Diclofenac Sandoz) and tab long-acting 75 mg (Apo-Diclo SR) – price increase and addition of HSS
 - Diclofenac sodium tab EC 25 mg (Diclofenac Sandoz) and tab long-acting 100 mg (Apo-Diclo SR) – price decrease and addition of HSS
 - Diltiazem hydrochloride (Apo-Diltiazem CD) cap long-acting 120 mg, 180 mg and 240 mg – price increase and addition of HSS
 - Dobutamine hydrochloride (Dobutamine-hameln) inj 12.5 mg per ml, 20 ml ampoule – new listing and to be delisted 1 January 2019
 - Enalapril maleate with hydrochlorothiazide tab 20 mg with hydrochlorothiazide 12.5 mg – to be delisted 1 January 2019
 - Entacavir (Entecavir Sandoz) tab 0.5 mg – new listing and addition of HSS
 - Entacavir (Baraclude) tab 0.5 mg – to be delisted 1 November 2018
 - Etidronate disodium (Arrow-Etidronate) tab 200 mg – to be delisted 1 January 2019
 - Fentanyl (Biomed) inj 20 mcg per ml, 50 ml syringe, 1 inj pack – new listing and addition of HSS
 - Fentanyl (Biomed) inj 20 mcg per ml, 50 ml syringe, 10 inj pack – to be delisted 1 October 2018
 - Ferrous sulphate (Ferrograd) tab long-acting 325 mg (105 mg elemental) – listing new Pharmacode and delisting existing Pharmacode
 - Flucloxacillin (AFT) grans for oral liq 25 mg per ml and 50 mg per ml – addition of HSS
 - Fluorouracil (Flourouracil Ebewe) inj 50 mg per ml, 20 ml vial – price increase and addition of HSS
 - Fluorouracil (Flourouracil Ebewe) inj 50 mg per ml, 100 ml vial – addition of HSS
 - Folic acid (Apo-Folic Acid) tab 0.8 mg and 5 mg – price increase and addition of HSS
 - Gabapentin (Arrow-Gabapentin, Neurontin and Nupentin) capsule 100 mg, 300 mg and 400 mg – restriction removed and delisted 1 August 2018
-

Summary of decisions – effective 1 August 2018 (continued)

- Glibenclamide (Daonil) tab 5 mg – new listing and addition of HSS
- Glycerol (PSM) suppos 3.6 g – price increase and addition of HSS
- Imiglucerase inj 40 iu per ml, 5 ml and 10 ml vials – to be delisted 1 March 2019
- Isoniazid (PSM) tab 100 mg – price increase and addition of HSS
- Isotretinoin (Oratane) cap 5 mg – new listing and addition of HSS
- Isotretinoin (Oratane) cap 10 mg and 20 mg – price decrease and addition of HSS
- Isotretinoin cap 10 mg (Isotane 10) and 20 mg (Isotane 20) – to be delisted 1 October 2018
- Isradipine cap long-acting 2.5 mg and 5 mg – to be delisted 1 October 2018
- Linezolid (Zyvox) tab 600 mg – price decrease and addition of HSS
- Megestrol acetate (Apo-Megestrol) tab 160 mg – price increase and addition of HSS
- Meloxicam tab 7.5 mg – to be delisted 1 November 2018
- Meropenem (Meropenem Ranbaxy) inj 500 mg and 1 g vials – new listing and addition of HSS
- Meropenem (DBL Meropenem) inj 500 mg and 1 g vials – to be delisted 1 October 2018
- Methadone hydrochloride oral liq 2 mg per ml (Biodone), 5 mg per ml (Biodone Forte), and 10 mg per ml (Biodone Extra Forte) – price increase and addition of HSS
- Metoprolol tartrate (Metoprolol IV Mylan) inj 1 mg per ml, 5 ml vial – new listing and addition of HSS
- Metoprolol tartrate (Lopressor) inj 1 mg per ml, 5 ml vial – to be delisted 1 February 2019
- Metoprolol tartrate (Apo-Metoprolol) tab 50 mg and 100 mg – price increase and addition of HSS
- Mirtazapine (Apo-Mirtazapine) tab 30 mg and 45 mg – price increase and addition of HSS
- Nadolol (Apo-Nadolol) tab 40 mg and 80 mg – price increase and addition of HSS
- Naproxen tab long-acting 750 mg (Naprosyn SR 750) and tab long-acting 1 g (Naprosyn SR 1000) – price increase and addition of HSS
- Nifedipine (Adalat Oros) tab long-acting 30 mg – HSS suspended

Summary of decisions – effective 1 August 2018 (continued)

- Olanzapine (Zyprexa Relprevv) inj 210 mg, 300 mg and 405 mg vials – price decrease and addition of HSS
 - Oxytocin with ergometrine maleate (Syntometrine) inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml ampoule – price increase and addition of HSS
 - Phenobarbitone (PSM) tab 15 mg and 30 mg – price increase and addition of HSS
 - Pindolol (Apo-Pindolol) tab 5 mg, 10 mg and 15 mg – price increase and addition of HSS
 - Pioglitazone (Vexazone) tab 15 mg, 30 mg and 45 mg – addition of HSS
 - Potassium chloride (Span-K) tab long-acting 600 mg (8 mmol) – price increase and addition of HSS
 - Potassium citrate (Biomed) oral liq 3 mmol per ml, 200 ml – price increase and addition of HSS
 - Propranolol (Apo-Propranolol) tab 10 mg and 40 mg – price increase and addition of HSS
 - Rivaroxaban (Xarelto) tab 10 mg, 15 tab pack – price decrease and restriction removed
 - Rivaroxaban (Xarelto) tab 10 mg, 15 mg and 20 mg – new listing
 - Salbutamol (Asthalin) nebuliser soln 1 mg per ml, 2.5 ml ampoule and 2 mg per ml, 2.5 ml ampoule – price increase and addition of HSS
 - Salbutamol with ipratropium bromide (Duolin) nebuliser soln 2.5 mg with ipratropium bromide 0.5 mg per 2.5 ml ampoule – price increase and addition of HSS
 - Simeticone oral drops 20 mg per 0.3 ml – new listing
 - Simeticone oral drops 100 mg per ml – amended chemical name
 - Sodium dihydrogen phosphate [sodium acid phosphate] (Biomed) inj 1 mmol per ml, 20 ml ampoule – price increase and addition of HSS
 - Sodium fusidate [fusidic acid] (Fucithalmic) eye drops 1%, 5 g – price increase
 - Somatropin (Omnitrope) inj 5 mg, 10 mg and 15 mg cartridges – price decrease and addition of HSS
 - Taliglucerase alfa (Elelyso) inj 200 unit vial – new listing
 - Tranexamic acid (Tranexamic-AFT) inj 100 mg per ml, 10 ml ampoule – pack size correction from 10 to 5 inj
 - Trandolapril cap 1 mg and 2 mg – to be delisted 1 January 2019
 - Trimethoprim (TMP) tab 300 mg – price increase and addition of HSS
-

Summary of decisions – effective 1 August 2018 (continued)

- Verapamil hydrochloride (Isoptin) tab 80 mg – listing new Pharmacode and delisting existing Pharmacode
- Ziprasidone (Zusdone) cap 20 mg – HSS delayed until further notice

Price
(ex man. Excl. GST)
\$ Per

Brand or
Generic
Manufacturer

Section H changes to Part II

Effective 1 August 2018

ALIMENTARY TRACT AND METABOLISM

5	ALUMINIUM HYDROXIDE WITH MAGNESIUM HYDROXIDE AND SIMETICONE SIMETHICONE (amended chemical name and presentation description) Tab 200 mg with magnesium hydroxide 200 mg and simeticone simethicone 20 mg Oral liq 400 mg with magnesium hydroxide 400 mg and simeticone simethicone 30 mg per 5 ml				<i>e.g. Mylanta</i> <i>e.g. Mylanta Double Strength</i>
5	SIMETICONE SIMETHICONE (amended chemical name) Oral drops 100 mg per ml				
5	SIMETICONE (new listing) Oral drops 20 mg per 0.3 ml				
10	GLIBENCLAMIDE (new listing) Tab 5 mg – 1% DV Oct-18 to 2021	6.00	100		Daonil
10	PIOGLITAZONE (addition of HSS) Tab 15 mg – 1% DV Oct-18 to 2021	3.47	90		Vexazone
	Tab 30 mg – 1% DV Oct-18 to 2021	5.06	90		Vexazone
	Tab 45 mg – 1% DV Oct-18 to 2021	7.10	90		Vexazone
12	GLYCEROL (↑ price and addition of HSS) Suppos 3.6 g – 1% DV Oct-18 to 2021	9.25	20		PSM
15	IMIGLUCERASE (delisting) → Inj 40 iu per ml, 5 ml vial → Inj 40 iu per ml, 10 ml vial Note – Imiglucerase inj 40 iu per ml, 5 ml and 10 ml vials to be delisted from 1 March 2019.				
16	TALIGLUCERASE ALFA (new listing) → Inj 200 unit vial	1,072.00	1		Elelyso
	Restricted Initiation Only for use in patients with approval by the Gaucher's Treatment Panel.				
17	FERROUS SULPHATE (Pharmacode change) Tab long-acting 325 mg (105 mg elemental) – 1% DV Jun-18 to 2021	2.06	30		Ferrograd
	Note – this is a new Pharmacode listing, 2534819. 604321 to be delisted from 1 February 2019.				

BLOOD AND BLOOD FORMING ORGANS

23	FOLIC ACID (↑ price and addition of HSS) Tab 0.8 mg – 1% DV Oct-18 to 2021	21.84	1,000		Apo-Folic Acid
	Tab 5 mg – 1% DV Oct-18 to 2021	12.12	500		Apo-Folic Acid

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

		Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer
Changes to Section H Part II – effective 1 August 2018 (continued)			
25	TRANEXAMIC ACID (pack size correction) Inj 100 mg per ml, 10 ml ampoule – 1% DV Sep-18 to 2021 ... 10.95 Note – this is a correction to the pack size only.	5 40	Tranexamic-AFT
28	RIVAROXABAN (↓ price and restriction removed) → Tab 10 mg 41.55 Restricted Initiation – total hip replacement <i>Limited to 5 weeks treatment</i> For the prophylaxis of venous thromboembolism. Initiation – total knee replacement <i>Limited to 2 weeks treatment</i> For the prophylaxis of venous thromboembolism.	15	Xarelto
28	RIVAROXABAN (new listing) Tab 10 mg 83.10 Tab 15 mg 77.56 Tab 20 mg 77.56	30 28 28	Xarelto Xarelto Xarelto
33	SODIUM DIHYDROGEN PHOSPHATE [SODIUM ACID PHOSPHATE] (↑ price and addition of HSS) Inj 1 mmol per ml, 20 ml ampoule – 1% DV Oct-18 to 2021 48.70	5	Biomed
33	POTASSIUM CHLORIDE (↑ price and addition of HSS) Tab long-acting 600 mg (8 mmol) – 1% DV Oct-18 to 2021 8.90	200	Span-K

CARDIOVASCULAR SYSTEM

35	TRANDOLAPRIL (delisting) → Cap 1 mg → Cap 2 mg Note – Trandolapril cap 1 mg and 2 mg to be delisted from 1 January 2019.		
35	ENALAPRIL MALEATE WITH HYDROCHLOROTHIAZIDE (delisting) → Tab 20 mg with hydrochlorothiazide 12.5 mg Note – Enalapril maleate with hydrochlorothiazide tab 20 mg with hydrochlorothiazide 12.5 mg to be delisted from 1 January 2019.		
37	ATROPINE SULPHATE (brand change) Inj 600 mcg per ml, 1 ml ampoule – 1% DV Oct-18 to 2021 12.07 Note – AstraZeneca inj 600 mcg per ml, 1 ml ampoule to be delisted from 1 October 2018.	10	Martindale
38	METOPROLOL TARTRATE (brand change) Inj 1 mg per ml, 5 ml vial – 1% DV Feb-19 to 31 Jan 2022 29.50 Note – Lopresor inj 1 mg per ml, 5 ml vial to be delisted from 1 February 2019.	5	Metoprolol IV Mylan
38	METOPROLOL TARTRATE (↑ price and addition of HSS) Tab 50 mg – 1% DV Oct-18 to 2021 5.66 Tab 100 mg – 1% DV Oct-18 to 2021 7.55	100 60	Apo-Metoprolol Apo-Metoprolol

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
Changes to Section H Part II – effective 1 August 2018 (continued)				
38	NADOLOL (↑ price and addition of HSS)			
	Tab 40 mg – 1% DV Oct-18 to 2021	16.69	100	Apo-Nadolol
	Tab 80 mg – 1% DV Oct-18 to 2021	26.43	100	Apo-Nadolol
38	PINDOLOL (↑ price and addition of HSS)			
	Tab 5 mg – 1% DV Oct-18 to 2021	13.22	100	Apo-Pindolol
	Tab 10 mg – 1% DV Oct-18 to 2021	23.12	100	Apo-Pindolol
	Tab 15 mg – 1% DV Oct-18 to 2021	33.31	100	Apo-Pindolol
38	PROPRANOLOL (↑ price and addition of HSS)			
	Tab 10 mg – 1% DV Oct-18 to 2021	4.64	100	Apo-Propranolol
	Tab 40 mg – 1% DV Oct-18 to 2021	5.72	100	Apo-Propranolol
39	ISRADIPINE (delisting)			
	Cap long-acting 2.5 mg			
	Cap long-acting 5 mg			
	Note – Isradipine cap long-acting 2.5 mg and 5 mg to be delisted from 1 October 2018.			
39	DILTIAZEM HYDROCHLORIDE (↑ price and addition of HSS)			
	Cap long-acting 120 mg – 1% DV Oct-18 to 2021	33.42	500	Apo-Diltiazem CD
	Cap long-acting 180 mg – 1% DV Oct-18 to 2021	50.05	500	Apo-Diltiazem CD
	Cap long-acting 240 mg – 1% DV Oct-18 to 2021	66.76	500	Apo-Diltiazem CD
39	NIFEDIPINE (HSS suspended)			
	Tab long-acting 30 mg – 1% DV Dec-17 to 31 Jul 18 2020	3.14	30	Adalat Oros
40	VERAPAMIL HYDROCHLORIDE (Pharmacode change)			
	Tab 80 mg	11.74	100	Isoptin
	Note – this is a listing of a new Pharmacode, 2535335. Pharmacode 253502 to be delisted from 1 July 2019.			
40	CLONIDINE HYDROCHLORIDE (↓ price and addition of HSS)			
	Tab 25 mcg – 1% DV Oct-18 to 2021	8.75	112	Clonidine BNM
40	CLONIDINE HYDROCHLORIDE (brand change)			
	Inj 150 mcg per ml, 1 ml ampoule – 1% DV Oct-18 to 2021	25.96	10	Medsurge
	Note – Catapres inj 150 mcg per ml, 1 ml ampoule to be delisted from 1 October 2018.			
43	DOBUTAMINE HYDROCHLORIDE (brand change)			
	Inj 12.5 mg per ml, 20 ml ampoule	61.13	5	Dobutamine-hameln
	Note – Dobutamine-hameln inj 12.5 mg per ml, 20 ml ampoule to be delisted from 1 January 2019.			
45	BOSENTAN (brand change)			
	→ Tab 62.5 mg – 1% DV Dec-18 to 2021	141.00	60	Bosentan Dr Reddy's
	→ Tab 125 mg – 1% DV Dec-18 to 2021	141.00	60	Bosentan Dr Reddy's
	Note – Bosentan-Mylan tab 62.5 mg and 125 mg to be delisted from 1 December 2018.			

DERMATOLOGICALS

50	ISOTRETINOIN (new listing)			
	Cap 5 mg – 1% DV Oct-18 to 2021	8.14	60	Oratane

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2018 (continued)

50	ISOTRETINOIN (↓ price and addition of HSS)			
	Cap 10 mg – 1% DV Oct-18 to 2021	13.34	120	Oratane
	Cap 20 mg – 1% DV Oct-18 to 2021	20.49	120	Oratane
50	ISOTRETINOIN (delisting)			
	Cap 10 mg	12.47	100	Isotane 10
	Cap 20 mg	19.27	100	Isotane 20
	Note – Isotane 10 cap 10 mg and Isotane 20 cap 20 mg to be delisted from 1 October 2018.			
51	AQUEOUS CREAM (↑ price and addition of HSS)			
	Crn 100 g – 1% DV Oct-18 to 2021	1.05	100 g	Pharmacy Health SLS-free
	Note: DV limit applies to the pack sizes of 100 g or less.			
52	BETAMETHASONE VALERATE (↑ price and addition of HSS)			
	Crn 0.1% – 1% DV Oct-18 to 2021	3.45	50 g	Beta Cream
	Oint 0.1% – 1% DV Oct-18 to 2021	3.45	50 g	Beta Ointment
53	BETAMETHASONE VALERATE (addition of HSS)			
	Scalp app 0.1% – 1% DV Oct-18 to 2021	7.75	100 ml	Beta Scalp

GENITO-URINARY SYSTEM

57	OXYTOCIN WITH ERGOMETRINE MALEATE (↑ price and addition of HSS)			
	Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml ampoule – 1% DV Oct-18 to 2021	15.00	5	Syntometrine
58	POTASSIUM CITRATE (↑ price and addition of HSS)			
	→ Oral liq 3 mmol per ml – 1% DV Oct-18 to 2021	31.80	200 ml	Biomed

HORMONE PREPARATIONS

61	DEXAMETHASONE (↑ price and addition of HSS)			
	Tab 0.5 mg – 1% DV Oct-18 to 2021	0.99	30	Dexamethosone
	Tab 4 mg – 1% DV Oct-18 to 2021	1.90	30	Dexamethosone
64	SOMATROPIN (↓ price and addition of HSS)			
	→ Inj 5 mg cartridge – 1% DV Oct-18 to 2021	34.88	1	Omnitrope
	→ Inj 10 mg cartridge – 1% DV Oct-18 to 2021	69.75	1	Omnitrope
	→ Inj 15 mg cartridge – 1% DV Oct-18 to 2021	104.63	1	Omnitrope

INFECTIONS

71	MEROPENEM (brand change)			
	→ Inj 500 mg vial – 1% DV Oct-18 to 2020	4.00	1	Meropenem Ranbaxy
	→ Inj 1 g vial – 1% DV Oct-18 to 2020	8.00	1	Meropenem Ranbaxy
	Note – DBL Meropenem inj 500 mg and 1 g vial to be delisted from 1 October 2018.			

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2018 (continued)

71	CEFALEXIN (↑ price and addition of HSS)			
	Grans for oral liq 25 mg per ml – 1% DV Oct-18 to 2021	8.75	100 ml	Cefalexin Sandoz
	Grans for oral liq 50 mg per ml – 1% DV Oct-18 to 2021	11.75	100 ml	Cefalexin Sandoz
74	FLUCLOXACILLIN (addition of HSS)			
	Grans for oral liq 25 mg per ml – 1% DV Oct-18 to 2021	2.29	100 ml	AFT
	Grans for oral liq 50 mg per ml – 1% DV Oct-18 to 2021 (↑ price)	3.68	100 ml	AFT
75	CIPROFLOXACIN (↑ price and addition of HSS)			
	→ Inj 2 mg per ml, 100 ml bag – 1% DV Oct-18 to 2021	68.20	10	Ciproflx
77	LINEZOLID (↓ price and addition of HSS)			
	→ Tab 600 mg – 1% DV Oct-18 to 2021	553.77	10	Zyvox
77	TRIMETHOPRIM (↑ price and addition of HSS)			
	Tab 300 mg – 1% DV Oct-18 to 2021	16.50	50	TMP
80	ISONIAZID (↑ price and addition of HSS)			
	→ Tab 100 mg – 1% DV Oct-18 to 2021	22.00	100	PSM
86	ENTECAVIR (new listing)			
	Tab 0.5 mg – 1% DV Nov-18 to 2021	52.00	30	Entecavir Sandoz
	Note – Baraclude tab 0.5 mg to be delisted from 1 November 2018.			

MUSCULOSKELETAL SYSTEM

94	ETIDRONATE DISODIUM (delisting)			
	Tab 200 mg	13.50	100	Arrow-Etidronate
	Note – Arrow-Etidronate tab 200 mg to be delisted from 1 January 2019.			
100	BACLOFEN (↑ price and addition of HSS)			
	Tab 10 mg – 1% DV Oct-18 to 2021	4.20	100	Pacifen
101	DICLOFENAC SODIUM (↑ price and addition of HSS)			
	Tab EC 50 mg – 1% DV Oct-18 to 2021	1.23	50	Diclofenac Sandoz
	Tab long-acting 75 mg – 1% DV Oct-18 to 2021	22.80	500	Apo-Diclo SR
101	DICLOFENAC SODIUM (↓ price and addition of HSS)			
	Tab EC 25 mg – 1% DV Oct-18 to 2021	1.23	50	Diclofenac Sandoz
	Tab long-acting 100 mg – 1% DV Oct-18 to 2021	25.15	500	Apo-Diclo SR
102	MELOXICAM (delisting)			
	→ Tab 7.5 mg			
	Note – Meloxicam tab 7.5 mg to be delisted from 1 November 2018			
102	NAPROXEN (↑ price and addition of HSS)			
	Tab long-acting 750 mg – 1% DV Oct-18 to 2021	6.16	28	Naprosyn SR 750
	Tab long-acting 1 g – 1% DV Oct-18 to 2021	8.21	28	Naprosyn SR 1000

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2018 (continued)

NERVOUS SYSTEM

108	FENTANYL (pack size change) Inj 20 mcg per ml, 50 ml syringe – 1% DV Oct-18 to 2021 18.74	1	Biomed
	Note – Biomed inj 20 mcg per ml, 50 ml syringe, 10 pack to be delisted 1 October 2018.		
108	METHADONE HYDROCHLORIDE (↑ price and addition of HSS) Oral liq 2 mg per ml – 1% DV Oct-18 to 2021 5.79	200 ml	Biodone
	Oral liq 5 mg per ml – 1% DV Oct-18 to 2021 5.79	200 ml	Biodone Forte
	Oral liq 10 mg per ml – 1% DV Oct-18 to 2021 6.79	200 ml	Biodone Extra Forte
110	CLOMIPRAMINE HYDROCHLORIDE (↑ price and addition of HSS) Tab 10 mg – 1% DV Oct-18 to 2021 13.99	100	Apo-Clomipramine
	Tab 25 mg – 1% DV Oct-18 to 2021 9.46	100	Apo-Clomipramine
111	MIRTAZAPINE (↑ price and addition of HSS) Tab 30 mg – 1% DV Oct-18 to 2021 2.63	30	Apo-Mirtazapine
	Tab 45 mg – 1% DV Oct-18 to 2021 3.48	30	Apo-Mirtazapine
112	GABAPENTIN (restriction removed and brands delisted) Note: Gabapentin not to be given in combination with pregabalin Capsule 100 mg 7.16	100	Arrow-Gabapentin Neurontin Nupentin
	Capsule 300 mg 11.00	100	Arrow-Gabapentin Neurontin Nupentin
	Capsule 400 mg 13.75	100	Arrow-Gabapentin Neurontin Nupentin

Restricted

Initiation – preoperative and/or postoperative use

Limited to 8 days treatment

Initiation – pain management of burns patients

Re-assessment required after 1 month

Continuation – pain management of burns patients

Re-assessment required after 1 month

The treatment remains appropriate and the patient is benefiting from treatment.

Initiation – epilepsy

Re-assessment required after 15 months

Either:

1 – Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or

2 – Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents.

Note: “Optimal treatment with other antiepilepsy agents” is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient’s age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

Continuation – epilepsy

Patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life.

continued...

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2018 (continued)

continued...

Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective

Initiation – Neuropathic pain or Chronic Kidney Disease-associated pruritus

Re-assessment required after 3 months

Either:

1 The patient has been diagnosed with neuropathic pain; or

2 Both:

2.1 The patient has Chronic Kidney Disease Stage 5-associated pruritus* where no other cause for pruritus can be identified (e.g. scabies, allergy); and

2.2 The patient has persistent pruritus not relieved with a trial of emollient/moisturising creams alone.

Continuation – Neuropathic pain or Chronic Kidney Disease-associated pruritus

Either:

1 The patient has demonstrated a marked improvement in their control of pain or itch (prescriber determined); or

2 The patient has previously demonstrated clinical responsiveness to gabapentin and has now developed neuropathic pain in a new site.

Note: Indications marked with * are unapproved indications. Dosage adjustment of gabapentin is recommended for patients with renal impairment.

Note – Arrow-Gabapentin, Narontin and Nupentin brands of gabapentin cap 100 mg, 300 mg and 400 mg to be delisted 1 August 2018.

114	PHENOBARBITONE (↑ price and addition of HSS)			
	Tab 15 mg – 1% DV Oct-18 to 2021	40.00	500	PSM
	Tab 30 mg – 1% DV Oct-18 to 2021	40.00	500	PSM
120	ZIPRASIDONE (HSS delayed)			
	Cap 20 mg – 1% DV Sep-18 to 2021	14.50	60	Zusdone
120	OLANZAPINE (↓ price and addition of HSS)			
	→ Inj 210 mg vial – 1% DV Oct-18 to 2021	252.00	1	Zyprexa Relprev
	→ Inj 300 mg vial – 1% DV Oct-18 to 2021	414.00	1	Zyprexa Relprev
	→ Inj 405 mg vial – 1% DV Oct-18 to 2021	504.00	1	Zyprexa Relprev
124	DEXAMFETAMINE SULFATE (↑ price and addition of HSS)			
	→ Tab 5 mg – 1% DV Oct-18 to 2021	20.00	100	PSM

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

130	CYCLOPHOSPHAMIDE (↑ price and addition of HSS)			
	Inj 1 g vial – 1% DV Oct-18 to 2021	35.65	1	Endoxan
	Inj 2 g vial – 1% DV Oct-18 to 2021	71.25	1	Endoxan
131	FLUOROURACIL (addition of HSS)			
	Inj 50 mg per ml, 20 ml vial – 1% DV Oct-18 to 2021 (↑ price)	12.00	1	Fluorouracil Ebewe
	Inj 50 mg per ml, 100 ml vial – 1% DV Oct-18 to 2021	30.00	1	Fluorouracil Ebewe
143	MEGESTROL ACETATE (↑ price and addition of HSS)			
	Tab 160 mg – 1% DV Oct-18 to 2021	63.53	30	Apo-Megestrol

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2018 (continued)

RESPIRATORY SYSTEM AND ALLERGIES

186	BUDESONIDE (brand change) Nasal spray 50 mcg per dose – 1% DV Oct-18 to 2020	2.59	200 dose	SteroClear
	Nasal spray 100 mcg per dose – 1% DV Oct-18 to 2020	2.87	200 dose	SteroClear
	Note – Butacort Aqueous nasal spray 50 mcg and 100 mcg per dose to be delisted from 1 October 2018.			
186	SALBUTAMOL WITH IPRATROPIUM BROMIDE (↑ price and addition of HSS) Nebuliser soln 2.5 mg with ipratropium bromide 0.5 mg per 2.5 ml ampoule – 1% DV Oct-18 to 2021	5.20	20	Duolin
188	SALBUTAMOL (↑ price and addition of HSS) Nebuliser soln 1 mg per ml, 2.5 ml ampoule – 1% DV Oct-18 to 2021	3.93	20	Asthalin
	Nebuliser soln 2 mg per ml, 2.5 ml ampoule – 1% DV Oct-18 to 2021	4.03	20	Asthalin
191	BERACTANT (delisting) Soln 200 mg per 8 ml vial	550.00	1	Survanta
	Note – Survanta soln 200 mg per 8 ml vial to be delisted from 1 January 2019.			

SENSORY ORGANS

192	SODIUM FUSIDATE [FUSIDIC ACID] (↑ price) Eye drops 1%	5.29	5 g	Fucithalmic
-----	--	------	-----	-------------

Index

Pharmaceuticals and brands

A		
Adalat Oros	10	
Aluminium hydroxide with magnesium hydroxide and simethicone	8	
Aluminium hydroxide with magnesium hydroxide and simeticone	8	
Apo-Clomipramine	13	
Apo-Diclo SR	12	
Apo-Diltiazem CD	10	
Apo-Folic Acid	8	
Apo-Megestrol	14	
Apo-Metoprolol	9	
Apo-Mirtazapine	13	
Apo-Nadolol	10	
Apo-Pindolol	10	
Apo-Propranolol	10	
Aqueous cream	11	
Arrow-Etidronate	12	
Arrow-Gabapentin	13	
Asthalin	15	
Atropine sulphate	9	
B		
Baclofen	12	
Beractant	15	
Beta Cream	11	
Betamethasone valerate	11	
Beta Ointment	11	
Beta Scalp	11	
Biodone	13	
Biodone Extra Forte	13	
Biodone Forte	13	
Bosentan	10	
Bosentan Dr Reddy's	10	
Budesonide	15	
C		
Cefalexin	12	
Cefalexin Sandoz	12	
Cipflox	12	
Ciprofloxacin	12	
Clomipramine hydrochloride	13	
Clonidine BNM	10	
Clonidine hydrochloride	10	
Cyclophosphamide	14	
D		
Daonil	8	
Dexamethasone	11	
Dexamfetamine sulfate	14	
Dexmethsone	11	
Diclofenac Sandoz	12	
Diclofenac sodium	12	
Diltiazem hydrochloride	10	
Dobutamine-hameln	10	
Dobutamine hydrochloride	10	
Duolin	15	
E		
Ellyso	8	
Enalapril maleate with hydrochlorothiazide	9	
Endoxan	14	
Entecavir	12	
Entecavir Sandoz	12	
Etidronate disodium	12	
F		
Fentanyl	13	
Ferrograd	8	
Ferrous sulphate	8	
Flucloxacillin	12	
Fluorouracil	14	
Fluorouracil Ebewe	14	
Folic acid	8	
Fucithalmic	15	
Fusidic acid	15	
G		
Gabapentin	13	
Glibenclamide	8	
Glycerol	8	
I		
Imiglucerase	8	
Isoniazid	12	
Isoptin	10	
Isotane 10	11	
Isotane 20	11	
Isotretinoin	10, 11	
Isradipine	10	
L		
Linezolid	12	
M		
Megestrol acetate	14	
Meloxicam	12	
Meropenem	11	
Meropenem Ranbaxy	11	
Methodone hydrochloride	13	
Metoprolol IV Mylan	9	
Metoprolol tartrate	9	
Mirtazapine	13	
Mylanta	8	
Mylanta Double Strength	8	
N		
Nadolol	10	
Naprosyn SR 750	12	
Naprosyn SR 1000	12	
Naproxen	12	
Neurontin	13	

Index

Pharmaceuticals and brands

Nifedipine.....	10	Sodium dihydrogen phosphate [sodium acid phosphate].....	9
Nupentin.....	13	Sodium fusidate [fusidic acid].....	15
O		Somatropin.....	11
Olanzapine.....	14	Span-K.....	9
Omnitrope.....	11	SteroClear.....	15
Oratane.....	10, 11	Survanta.....	15
Oxytocin with ergometrine maleate.....	11	Syntometrine.....	11
P		T	
Pacifen.....	12	Taliglucerase alfa.....	8
Pharmacy Health SLS-free.....	11	TMP.....	12
Phenobarbitone.....	14	Trandolapril.....	9
Pindolol.....	10	Tranexamic acid.....	9
Pioglitazone.....	8	Tranexamic-AFT.....	9
Potassium chloride.....	9	Trimethoprim.....	12
Potassium citrate.....	11	V	
Propranolol.....	10	Verapamil hydrochloride.....	10
R		Vexazone.....	8
Rivaroxaban.....	9	X	
S		Xarelto.....	9
Salbutamol.....	15	Z	
Salbutamol with ipratropium bromide.....	15	Ziprasidone.....	14
Simethicone.....	8	Zusdone.....	14
Simeticone.....	8	Zyprexa Relprevv.....	14
Sodium acid phosphate.....	9	Zyvox.....	12



Email: enquiry@pharmac.govt.nz

www.pharmac.govt.nz/medicines/hospital-pharmaceuticals

Pharmaceutical Management Agency

Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand
Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz

ISSN 1179-3694 (Print) - ISSN 1179-3708 (Online)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the Update.